DiRaimondo Thomas
Chief Scientific Officer
DiRaimondo Thomas has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jan 2, 2026.
On the most recent filing, DiRaimondo Thomas is listed as Chief Scientific Officer at Janux Therapeutics, Inc. Inside the rolling window, DiRaimondo Thomas reported no open-market purchases and 1 open-market sale totaling $34K in JANX.
Companies traded
Other insiders at JANX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$34K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has DiRaimondo Thomas made?
DiRaimondo Thomas has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does DiRaimondo Thomas trade?
DiRaimondo Thomas has filed SEC Form 4 disclosures for 1 company, including JANX.
When was DiRaimondo Thomas's most recent SEC Form 4 filing?
DiRaimondo Thomas's most recent SEC Form 4 filing on Tracefour is dated Jan 2, 2026.
What is DiRaimondo Thomas's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, DiRaimondo Thomas is listed as Chief Scientific Officer.
What is DiRaimondo Thomas's total buy and sell value in the current window?
Inside the rolling retention window, DiRaimondo Thomas bought $0 and sold $34K based on SEC Form 4 filings.
What was DiRaimondo Thomas's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,505 JANX shares on 2026-01-02, worth $34K, per SEC Form 4 filings.